Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Log inSign up
Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Blog
Job Board
Q3AS

© 2026 Aqora Quantum S.A.S.

TermsPrivacyLegal Notice

International Journal of Academic and Industrial Research Innovations(IJAIRI)

Quantum-Enhanced Generative Learning for Precision Genomics and Molecular Discovery

Murali Krishna Pasupuleti

Published Oct 30, 2026• 1 citation
Publisher

Abstract

Abstract Precision genomics and molecular discovery require generative systems that connect heterogeneous biological information with functional candidate design while controlling uncertainty, biological risk and computational expenditure. This study develops Quantum-Enhanced Genomic and Molecular Learning (QEGML), a conditional quantum–classical framework integrating a modality-aware encoder, a parameterized quantum latent distribution, a classical molecular or sequence decoder, and constrained candidate selection. The research combines a focused synthesis of relevant literature with mathematical derivation and transparent numerical scenario analysis. No new patient cohort, quantum-hardware experiment or biological assay is reported. Conditional likelihood and distributional regularization define training, while activity, off-target effects, toxicity, resource burden and predictive uncertainty determine selection. A four-candidate calculation shows that the highest assumed activity does not necessarily yield the preferred feasible candidate. With the declared weights, uncertainty adjustment changes the selected candidate from A to B, increasing the evaluated risk-adjusted utility from 0.650 to 0.715. The ranking crossover occurs at a risk-aversion coefficient of 0.1875. Independent-shot calculations further show that reducing the worst-case standard error of a binary measurement from 0.050 to 0.0125 requires increasing the shot count from 100 to 1,600. A published molecular-discovery example is considered separately from these calculations. Comparative analysis specifies matched classical controls, noise ablations and cost-aware evaluation without assigning unmeasured performance gains to the quantum component. The contribution is an auditable framework linking generative representation, decision reliability and experimental accountability. Its practical value remains conditional on prospective biological validation and demonstrable improvement over strong classical alternatives. Keywords: quantum generative learning; precision genomics; multi-omics integration; conditional generation; variational quantum circuits; quantum Born machines; molecular discovery; genomic language models; constrained optimization; uncertainty quantification; finite-shot sampling; model calibration; experimental validation; computational benchmarking.

DOI
10.62311/nesx/rp5oct-30102026

Related papers

Quantum Machine Learning for Multi-Omics Integration in Personalized Medicine and Predictive Diagnostics

Hande Selvi Yanık

Multi-omics integration has become a cornerstone of personalized medicine, enabling researchers to connect genomic, transcriptomic, proteomic, metabolomic, and epigenomic data to reveal complex biological mechanisms and individualized disease signatures. However, the extreme dimensionality, heterogeneity, and nonlinear interactions across omics layers challenge even the most advanced classical machine learning methods. Quantum Machine Learning (QML) offers a powerful alternative by exploiting quantum superposition, entanglement, and high-dimensional feature embeddings to model multi-omics interactions more efficiently. This study proposes a hybrid quantum–classical framework that combines quantum kernel estimation, variational quantum classifiers, and quantum-enhanced feature fusion networks to generate integrative biological signatures for precision diagnostics. Simulation results using benchmark multi-omics datasets demonstrate improved classification accuracy, enhanced sensitivity to weak biological signals, and reduced computational overhead compared to classical baselines. These findings highlight the potential of QML to accelerate multi-omics insights and pave the way toward truly personalized, predictive healthcare.

Next frontier.•Nov 28, 2025•0 citations

Quantum-Enhanced Conditional GAN for Targeted Molecule Design

Aakanksha Baidya, Manish Pratap Singh, Sanjay Kumar Dubey

Drug discovery for a given protein target is a complex, resource-intensive process, often requiring years of research and billions of dollars in investment. Computational techniques, particularly deep learning models, have accelerated molecular generation, but they remain constrained by classical computational limitations and reliance on known chemical patterns. To address these challenges, we propose a hybrid quantum conditional GAN with gradient penalty for drug design, integrating quantum computing to enhance exploration of the vast chemical space. The proposed approach leverages a hybrid classical and quantum generative model to create novel molecular structures while ensuring they adhere to chemical and pharmacological properties. By conditioning the generative model on protein target sequences, we improve molecular specificity, increasing the likelihood of discovering viable drug candidates. Our framework generates chemically valid, diverse, and target-specific molecules, offering a promising avenue for more efficient and precise data-driven drug discovery.

International Conference on Reliability, Infocom Technologies and Optimization (Trends and Future Directions) (ICRITO)•Sep 18, 2025•1 citation

An Uncertainty-Aware Adaptive Hybrid Quantum-Classical Learning Framework for Drug Discovery

A. Santhosh Nantha, M. Jayalakshmi, K. Maharajan +2 more

Quantum machine learning (QML) has attracted significant interest in drug discovery due to its potential to model complex molecular interactions and improve prediction accuracy for protein-ligand binding affinity. However, most existing hybrid quantum-classical approaches rely on static architectures that apply quantum computation uniformly across all samples, regardless of molecular complexity or prediction confidence. Such static execution strategies lead to inefficient quantum resource utilization and limit scalability on near-term noisy intermediatescale quantum (NISQ) devices. In this paper, we propose an uncertainty-aware adaptive hybrid quantum-classical learning framework for protein-ligand binding affinity prediction that treats quantum computation as a selectively invoked resource rather than a constant component of the learning pipeline. The proposed framework first employs a classical ensemble-based regression model to generate binding affinity predictions along with an associated uncertainty estimate derived from ensemble variance. This uncertainty information is then used by a decision mechanism to dynamically select between classical-only inference, shallow quantum circuit execution, or deep quantum circuit execution. By adapting the quantum circuit depth and invocation frequency to the predicted uncertainty, the framework enables decision-centric allocation of quantum resources. Experimental evaluation of binding affinity data demonstrates that the recommended adaptive framework utilizes around 76 % less quantum resources than static hybrid quantum learning methods that use fixed-depth quantum circuits for all samples. The framework also preserves decision-level functionality and a steady inference workflow. These findings highlight the effectiveness of uncertainty-guided adaptivity as a practical strategy and offer a scalable foundation for future quantum-enhanced molecular learning.method for incorporating QML into drug development pipelines while taking hardware constraints into consideration.

International Conference on Signal, Systems, and Computing for Next-Gen Automation (ICSSCNA)•May 4, 2026•0 citations

Quantum-Enhanced AI for Genomic Medicine

Shakila Basheer

By facilitating quicker and more precise analysis of intricate biological data, the union of quantum computing and Artificial Intelligence (AI) may transform genomic medicine and drug discovery altogether. The study suggests a model for artificial intelligence with quantum-enhanced acceleration based on hybrid quantum-classical models in order to speed up drug discovery and customize therapies. It utilizes deep learning models and Quantum Machine Learning (QML) techniques to analyze patient-specific data, protein structures, and genetic sequences. Large genomic and clinical data sets are processed by conventional deep learning models, while the quantum component carries out efficient data encoding and optimization processes. As compared to other traditional AI-based approaches, the proposed model performs a 30% improved drug target identification when evaluated against more than 1,000 genetic sequences and related clinical outcomes. The hybrid model was as accurate as 98.4% in its prediction and was more accurate than the conventional AI techniques including random forests (accuracy: 91.3%) and gradient boosting machines (accuracy: 93.7%). The methodology also produced an F1-score of 0.95 with accuracy and recall scores of 96.1% and 94.7%, respectively. These results demonstrate how quantum-enhanced AI can reduce the time for computation and improve the accuracy of genomic data analysis, driving significant progress toward personalized therapy and drug development.

CRC Press eBooks•Jun 2, 2026•0 citations

Adaptive Quantum Approximate Optimization for Genomic Classification

Sthefanie Jofer Gomes Passo, Vishal H. Kothavade, John Jeffery Prevost

Abstract Quantum machine learning for genomic sequence classification faces three compounding constraints on current hardware: barren plateaus in variational training, exponential concentration of quantum kernel expressivity in highdimensional feature spaces, and noise accumulation that limits practical circuit depth to fewer than 50 layers on current NISQ devices. Existing quantum genomics studies address these constraints using fixed-architecture circuits without noise-calibrated validation on standardized benchmarks, leaving the potential of adaptive circuit topology largely unexplored. Three QAOA variants are developed and systematically compared to address this gap. Classical QAOA establishes a baseline using fixed p-layer circuits with standard phase and mixing operators. Alternating QAOA introduces structured CNOT entanglement between alternating qubit pairs to evaluate whether non-local correlations improve genomic pattern recognition. The primary contribution, Adaptive QAOA, employs gradient-driven operator selection from feature-weighted Pauli operator pools, generating variable-depth problemspecific circuits that adapt their topology to dataset structure rather than applying universal ans¨atze. All three architectures are evaluated through quantum simulation on two standardized genomic benchmarks: Human Nontata Promoters (36,131 sequences) and Demo Coding vs. Intergenic Sequences (100,000 sequences). Experiments are conducted under both noiseless conditions and noise models calibrated to IBM superconducting hardware specifications, across feature space dimensionalities ranging from 2 to 10 dimensions using 10-fold cross-validation. Adaptive QAOA consistently achieves the highest precision (approximately 75% under noiseless simulation) and maintains perfect specificity across both datasets and noise conditions, results not observed for fixed-depth variants. These performance gains are accompanied by reduced hardware resource consumption, with Adaptive QAOA requiring the fewest qubits and lowest quantum usage time (∼0.52–0.60 s) across most configurations. Superior coherence characteristics — average T1 of 82.12 μs and T2 of 55.45 μs, exceeding Classical QAOA by 13.6% and 113.3% respectively — provide a physical basis for reduced error accumulation under realistic noise constraints. All QAOA variants maintain stable classification performance across all tested dimensionalities, contrasting with compounding errors documented for fixed-architecture quantum kernel methods on high-dimensional genomic data. These results establish that gradient-driven adaptive circuit topology with domain-specific feature weighting represents a more effective design strategy than uniform depth scaling or entanglement-based ansatz modification for near-term quantum genomic classification.

•Sep 15, 2026•0 citations

Quantum Machine Learning in Precision Medicine and Drug Discovery - A Game Changer for Tailored Treatments?

Markus Bertl, Alan Mott, Salvatore Sinno +1 more

Abstract The digitization of healthcare presents numerous challenges, including the complexity of biological systems, vast data generation, and the need for personalized treatment plans. Traditional computational methods often fall short, leading to delayed and sometimes ineffective diagnoses and treatments. Quantum Computing (QC) and Quantum Machine Learning (QML) offer transformative advancements with the potential to revolutionize medicine by leveraging quantum mechanics principles. This paper summarizes areas where QC promises unprecedented computational power, enabling faster, more accurate diagnostics, personalized treatments, and enhanced drug discovery processes. However, integrating quantum technologies into precision medicine also presents challenges, including errors in algorithms and high costs. We show that mathematically-based techniques for specifying, developing, and verifying software (formal methods) can enhance the reliability and correctness of QC. By providing a rigorous mathematical framework, formal methods help to specify, develop, and verify systems with high precision. In genomic data analysis, formal specification languages can precisely (1) define the behavior and properties of quantum algorithms designed to identify genetic markers associated with diseases. Model checking tools can systematically explore all possible states of the algorithm to (2) ensure it behaves correctly under all conditions, while theorem proving techniques provide mathematical (3) proof that the algorithm meets its specified properties, ensuring accuracy and reliability. Additionally, formal optimization techniques can (4) enhance the efficiency and performance of quantum algorithms by reducing resource usage, such as the number of qubits and gate operations. Therefore, we posit that formal methods can significantly contribute to enabling QC to realize its full potential as a game changer in precision medicine.

arXiv:2502.18639•Lecture notes in computer science•Sep 30, 2025•10 citations
Abstract Precision genomics and molecular discovery require generative systems that connect heterogeneous biological information with functional candidate design while controlling uncertainty, biological risk and computational expenditure. This study develops Quantum-Enhanced Genomic and Molecular Learning (QEGML), a conditional quantum–classical framework integrating a modality-aware encoder, a parameterized quantum latent distribution, a classical molecular or sequence decoder, and constrained candidate selection. The research combines a focused synthesis of relevant literature with mathematical derivation and transparent numerical scenario analysis. No new patient cohort, quantum-hardware experiment or biological assay is reported. Conditional likelihood and distributional regularization define training, while activity, off-target effects, toxicity, resource burden and predictive uncertainty determine selection. A four-candidate calculation shows that the highest assumed activity does not necessarily yield the preferred feasible candidate. With the declared weights, uncertainty adjustment changes the selected candidate from A to B, increasing the evaluated risk-adjusted utility from 0.650 to 0.715. The ranking crossover occurs at a risk-aversion coefficient of 0.1875. Independent-shot calculations further show that reducing the worst-case standard error of a binary measurement from 0.050 to 0.0125 requires increasing the shot count from 100 to 1,600. A published molecular-discovery example is considered separately from these calculations. Comparative analysis specifies matched classical controls, noise ablations and cost-aware evaluation without assigning unmeasured performance gains to the quantum component. The contribution is an auditable framework linking generative representation, decision reliability and experimental accountability. Its practical value remains conditional on prospective biological validation and demonstrable improvement over strong classical alternatives. Keywords: quantum generative learning; precision genomics; multi-omics integration; conditional generation; variational quantum circuits; quantum Born machines; molecular discovery; genomic language models; constrained optimization; uncertainty quantification; finite-shot sampling; model calibration; experimental validation; computational benchmarking.
Multi-omics integration has become a cornerstone of personalized medicine, enabling researchers to connect genomic, transcriptomic, proteomic, metabolomic, and epigenomic data to reveal complex biological mechanisms and individualized disease signatures. However, the extreme dimensionality, heterogeneity, and nonlinear interactions across omics layers challenge even the most advanced classical machine learning methods. Quantum Machine Learning (QML) offers a powerful alternative by exploiting quantum superposition, entanglement, and high-dimensional feature embeddings to model multi-omics interactions more efficiently. This study proposes a hybrid quantum–classical framework that combines quantum kernel estimation, variational quantum classifiers, and quantum-enhanced feature fusion networks to generate integrative biological signatures for precision diagnostics. Simulation results using benchmark multi-omics datasets demonstrate improved classification accuracy, enhanced sensitivity to weak biological signals, and reduced computational overhead compared to classical baselines. These findings highlight the potential of QML to accelerate multi-omics insights and pave the way toward truly personalized, predictive healthcare.
Drug discovery for a given protein target is a complex, resource-intensive process, often requiring years of research and billions of dollars in investment. Computational techniques, particularly deep learning models, have accelerated molecular generation, but they remain constrained by classical computational limitations and reliance on known chemical patterns. To address these challenges, we propose a hybrid quantum conditional GAN with gradient penalty for drug design, integrating quantum computing to enhance exploration of the vast chemical space. The proposed approach leverages a hybrid classical and quantum generative model to create novel molecular structures while ensuring they adhere to chemical and pharmacological properties. By conditioning the generative model on protein target sequences, we improve molecular specificity, increasing the likelihood of discovering viable drug candidates. Our framework generates chemically valid, diverse, and target-specific molecules, offering a promising avenue for more efficient and precise data-driven drug discovery.
Quantum machine learning (QML) has attracted significant interest in drug discovery due to its potential to model complex molecular interactions and improve prediction accuracy for protein-ligand binding affinity. However, most existing hybrid quantum-classical approaches rely on static architectures that apply quantum computation uniformly across all samples, regardless of molecular complexity or prediction confidence. Such static execution strategies lead to inefficient quantum resource utilization and limit scalability on near-term noisy intermediatescale quantum (NISQ) devices. In this paper, we propose an uncertainty-aware adaptive hybrid quantum-classical learning framework for protein-ligand binding affinity prediction that treats quantum computation as a selectively invoked resource rather than a constant component of the learning pipeline. The proposed framework first employs a classical ensemble-based regression model to generate binding affinity predictions along with an associated uncertainty estimate derived from ensemble variance. This uncertainty information is then used by a decision mechanism to dynamically select between classical-only inference, shallow quantum circuit execution, or deep quantum circuit execution. By adapting the quantum circuit depth and invocation frequency to the predicted uncertainty, the framework enables decision-centric allocation of quantum resources. Experimental evaluation of binding affinity data demonstrates that the recommended adaptive framework utilizes around 76 % less quantum resources than static hybrid quantum learning methods that use fixed-depth quantum circuits for all samples. The framework also preserves decision-level functionality and a steady inference workflow. These findings highlight the effectiveness of uncertainty-guided adaptivity as a practical strategy and offer a scalable foundation for future quantum-enhanced molecular learning.method for incorporating QML into drug development pipelines while taking hardware constraints into consideration.
By facilitating quicker and more precise analysis of intricate biological data, the union of quantum computing and Artificial Intelligence (AI) may transform genomic medicine and drug discovery altogether. The study suggests a model for artificial intelligence with quantum-enhanced acceleration based on hybrid quantum-classical models in order to speed up drug discovery and customize therapies. It utilizes deep learning models and Quantum Machine Learning (QML) techniques to analyze patient-specific data, protein structures, and genetic sequences. Large genomic and clinical data sets are processed by conventional deep learning models, while the quantum component carries out efficient data encoding and optimization processes. As compared to other traditional AI-based approaches, the proposed model performs a 30% improved drug target identification when evaluated against more than 1,000 genetic sequences and related clinical outcomes. The hybrid model was as accurate as 98.4% in its prediction and was more accurate than the conventional AI techniques including random forests (accuracy: 91.3%) and gradient boosting machines (accuracy: 93.7%). The methodology also produced an F1-score of 0.95 with accuracy and recall scores of 96.1% and 94.7%, respectively. These results demonstrate how quantum-enhanced AI can reduce the time for computation and improve the accuracy of genomic data analysis, driving significant progress toward personalized therapy and drug development.
Abstract Quantum machine learning for genomic sequence classification faces three compounding constraints on current hardware: barren plateaus in variational training, exponential concentration of quantum kernel expressivity in highdimensional feature spaces, and noise accumulation that limits practical circuit depth to fewer than 50 layers on current NISQ devices. Existing quantum genomics studies address these constraints using fixed-architecture circuits without noise-calibrated validation on standardized benchmarks, leaving the potential of adaptive circuit topology largely unexplored. Three QAOA variants are developed and systematically compared to address this gap. Classical QAOA establishes a baseline using fixed p-layer circuits with standard phase and mixing operators. Alternating QAOA introduces structured CNOT entanglement between alternating qubit pairs to evaluate whether non-local correlations improve genomic pattern recognition. The primary contribution, Adaptive QAOA, employs gradient-driven operator selection from feature-weighted Pauli operator pools, generating variable-depth problemspecific circuits that adapt their topology to dataset structure rather than applying universal ans¨atze. All three architectures are evaluated through quantum simulation on two standardized genomic benchmarks: Human Nontata Promoters (36,131 sequences) and Demo Coding vs. Intergenic Sequences (100,000 sequences). Experiments are conducted under both noiseless conditions and noise models calibrated to IBM superconducting hardware specifications, across feature space dimensionalities ranging from 2 to 10 dimensions using 10-fold cross-validation. Adaptive QAOA consistently achieves the highest precision (approximately 75% under noiseless simulation) and maintains perfect specificity across both datasets and noise conditions, results not observed for fixed-depth variants. These performance gains are accompanied by reduced hardware resource consumption, with Adaptive QAOA requiring the fewest qubits and lowest quantum usage time (∼0.52–0.60 s) across most configurations. Superior coherence characteristics — average T1 of 82.12 μs and T2 of 55.45 μs, exceeding Classical QAOA by 13.6% and 113.3% respectively — provide a physical basis for reduced error accumulation under realistic noise constraints. All QAOA variants maintain stable classification performance across all tested dimensionalities, contrasting with compounding errors documented for fixed-architecture quantum kernel methods on high-dimensional genomic data. These results establish that gradient-driven adaptive circuit topology with domain-specific feature weighting represents a more effective design strategy than uniform depth scaling or entanglement-based ansatz modification for near-term quantum genomic classification.
Abstract The digitization of healthcare presents numerous challenges, including the complexity of biological systems, vast data generation, and the need for personalized treatment plans. Traditional computational methods often fall short, leading to delayed and sometimes ineffective diagnoses and treatments. Quantum Computing (QC) and Quantum Machine Learning (QML) offer transformative advancements with the potential to revolutionize medicine by leveraging quantum mechanics principles. This paper summarizes areas where QC promises unprecedented computational power, enabling faster, more accurate diagnostics, personalized treatments, and enhanced drug discovery processes. However, integrating quantum technologies into precision medicine also presents challenges, including errors in algorithms and high costs. We show that mathematically-based techniques for specifying, developing, and verifying software (formal methods) can enhance the reliability and correctness of QC. By providing a rigorous mathematical framework, formal methods help to specify, develop, and verify systems with high precision. In genomic data analysis, formal specification languages can precisely (1) define the behavior and properties of quantum algorithms designed to identify genetic markers associated with diseases. Model checking tools can systematically explore all possible states of the algorithm to (2) ensure it behaves correctly under all conditions, while theorem proving techniques provide mathematical (3) proof that the algorithm meets its specified properties, ensuring accuracy and reliability. Additionally, formal optimization techniques can (4) enhance the efficiency and performance of quantum algorithms by reducing resource usage, such as the number of qubits and gate operations. Therefore, we posit that formal methods can significantly contribute to enabling QC to realize its full potential as a game changer in precision medicine.